
    
      OBJECTIVES:

      Primary

        -  Compare the incidence of marrow suppression with 2 methods of maintenance treatment in
           children with acute lymphoblastic leukemia.

        -  Compare the incidence of liver toxicity with 2 methods of maintenance treatment in these
           patients.

      Secondary

        -  Determine any difference in infection rates and related hospitalizations in these
           patients.

      OUTLINE: This is a multicenter study. Patients are stratified according to risk (high vs
      intermediate vs standard), age in years (0 to 5 vs 6 to 9 vs 10 to 17), and sex.

        -  Patients with standard-risk disease:

             -  Induction therapy: Patients receive prednisolone IV or orally three times daily on
                days 1-7; oral dexamethasone three times daily on days 8-28; asparaginase IV over 1
                hour or intramuscularly once on days 8, 11, 14, 17, 20, 23, 26, and 29; vincristine
                IV once on days 8, 15, 22, and 29; daunorubicin hydrochloride IV over 1 hour on
                days 8 and 15; and methotrexate intrathecally (IT) once on days 1, 15, and 33.

             -  Early intensification (EI) therapy: Patients receive cyclophosphamide IV over 1
                hour on day 36, cytarabine IV continuously on days 38-41 and 45-48, oral
                mercaptopurine once daily on days 36-50, and methotrexate IT on days 38 and 45.

             -  Consolidation therapy: Two weeks after completing EI therapy, patients receive oral
                mercaptopurine once daily on days 1-56 and methotrexate IV over 24 hours and IT on
                days 8, 22, 36, and 50.

             -  Delayed intensification (DI) therapy:

                  -  DI/a: Patients receive dexamethasone orally or IV three times daily on days
                     1-7 and 15-21, doxorubicin hydrochloride IV over 1 hour on days 1, 8, and 15;
                     vincristine IV on days 1, 8, and 15; and asparaginase subcutaneously (SC) or
                     IV over 1 hour on days 1, 4, 8, and 11.

                  -  DI/b: Patients receive cyclophosphamide IV over 1 hour on day 29, cytarabine
                     IV continuously on days 31-34 and 38-41, oral thioguanine once daily on days
                     29-42, and methotrexate IT on days 31 and 38.

             -  Maintenance therapy: Patients are randomized to one of two treatment arms. Patients
                who do not consent for randomization receive conventional therapy (arm I).

                  -  Arm I (conventional): Patients receive oral mercaptopurine and oral
                     methotrexate on days 1-56, dexamethasone IV on days 1-5 and 29-33, vincristine
                     IV on days 1 and 29, and methotrexate IT on day 50. Treatment repeats every 8
                     weeks for up to 8 courses for girls or 11 courses for boys.

                  -  Arm II (intervention): Patients receive oral mercaptopurine once daily on days
                     8-28 and 36-56; oral methotrexate once on days 8,15, 22, 36, 43, and 50;
                     dexamethasone IV on days 1-5 and 29-33; and vincristine IV on days 1 and 29.
                     Patients also receive methotrexate IT on day 1, every 8 weeks, for 8 courses.

        -  Patients with intermediate-risk disease:

             -  Induction therapy: Patients receive prednisolone, dexamethasone, and asparaginase
                as in standard-risk induction therapy. Patients also receive vincristine IV and
                daunorubicin hydrochloride IV over 1 hour on days 8, 15, 22, and 29; methotrexate
                IT on day 1; and triple intrathecal therapy (TIT; high-dose methotrexate,
                cytarabine, hydrocortisone sodium succinate) on days 15 and 33.

             -  First EI therapy: Patients receive cyclophosphamide, cytarabine, and mercaptopurine
                as in standard-risk EI. Patients also receive TIT on day 38.

             -  Second EI therapy: Beginning 2 weeks after completing first EI, patients receive
                cyclophosphamide over 1 hour on day 1, oral mercaptopurine on days 1-14, cytarabine
                IV on days 3-6 and 10-13, and TIT on day 3.

             -  Consolidation therapy: Beginning 2 weeks after completing second EI, patients
                receive mercaptopurine as in standard-risk consolidation therapy. Patients also
                receive methotrexate IV over 24 hours and TIT on days 8, 22, 36, and 50.

             -  First DI therapy: Patients receive treatment as in standard-risk DI.

             -  Interim maintenance therapy: Patients receive oral mercaptopurine and oral
                methotrexate on days 1-56.

             -  Second DI therapy: Patients receive DI/a and D1/b (without methotrexate) as in
                standard-risk DI. Patients also receive TIT on days 31 and 38.

             -  Maintenance therapy: Patients are randomized to 1 of 2 treatment arms:

                  -  Arm I (conventional): Patients receive mercaptopurine, methotrexate,
                     dexamethasone, and vincristine as in standard-risk maintenance therapy arm I.
                     Patients also receive TIT on day 50. Treatment repeats every 8 weeks for up to
                     8 courses for girls or 11 courses for boys.

                  -  Arm II (intervention): Patients receive treatment as in standard-risk
                     maintenance therapy arm II.

        -  Patients with high-risk disease:

             -  Induction therapy: Patients receive treatment as in intermediate-risk induction
                therapy.

             -  First EI therapy: Patients receive treatment as in intermediate-risk first EI.

             -  Second EI therapy: Patients receive treatment as in intermediate-risk second EI.

             -  Consolidation therapy (interval between blocks is 2 weeks):

                  -  Block 1: Patients receive dexamethasone orally or IV three times daily on days
                     1-5, vincristine IV on days 1 and 6, high-dose methotrexate IV over 24 hours
                     on day 1, cyclophosphamide IV over 1 hour twice daily on days 2-4, cytarabine
                     IV over 3 hours twice on day 5, asparaginase IV over 2 hours on days 6 and 11,
                     and TIT on day 1.

                  -  Block 2: Patients receive dexamethasone, high-dose methotrexate, asparaginase,
                     and TIT as in block 1. Patients also receive vindesine IV twice daily on days
                     1 and 6, ifosfamide IV over 1 hour twice daily on days 2-4, and daunorubicin
                     hydrochloride IV over 24 hours on day 5.

                  -  Block 3: Patients receive dexamethasone and asparaginase as in block 1.
                     Patients also receive high-dose cytarabine IV over 3 hours twice daily on days
                     1 and 2, etoposide IV over 1 hour five times on days 3-5, and TIT on day 5.

             -  Blocks 1-3 are then repeated once. Patients then proceed to delayed intensification
                therapy.

             -  Delayed intensification therapy: Patients receive dexamethasone orally or IV three
                times daily on days 1-7 and 15-21; doxorubicin hydrochloride IV and vincristine IV
                on days 8, 15, 22, and 29; and asparaginase IV on days 8, 11, 15, and 18. Patients
                also receive cyclophosphamide IV on day 36, cytarabine IV on days 38-41 and 45-48,
                thioguanine IV on days 36-49, and TIT on days 38 and 45.

             -  Maintenance therapy: Patients receive oral mercaptopurine and oral methotrexate
                once daily on days 1-14, cyclophosphamide over 1 hour and cytarabine over 1 hour
                once between days 15-21, oral dexamethasone two or three times daily for 5 days
                between days 29-35, vincristine IV on day 29, and TIT on day 22. Treatment repeats
                every 4 weeks. After 10 courses, patients no longer receive TIT. After 12 courses,
                patients no longer receive cyclophosphamide and cytarabine. At this time patients
                continue mercaptopurine and methotrexate on days 1-21. After 20 courses, patients
                no longer receive dexamethasone or vincristine. At this time, patients continue
                mercaptopurine and methotrexate on days 1-28. Females receive up to 17 courses and
                males up to 23 courses.

      Some patients may also undergo radiotherapy or stem cell transplantation.
    
  